FORA Capital LLC Invests $287,000 in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

FORA Capital LLC bought a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 22,643 shares of the biotechnology company’s stock, valued at approximately $287,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IRWD. Financial Counselors Inc. bought a new position in Ironwood Pharmaceuticals in the 4th quarter worth about $117,000. Cetera Advisor Networks LLC lifted its stake in Ironwood Pharmaceuticals by 8.8% during the 1st quarter. Cetera Advisor Networks LLC now owns 11,021 shares of the biotechnology company’s stock valued at $139,000 after acquiring an additional 893 shares during the period. Advisor Group Holdings Inc. lifted its stake in Ironwood Pharmaceuticals by 77.2% during the 4th quarter. Advisor Group Holdings Inc. now owns 14,432 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 6,289 shares during the period. Parametrica Management Ltd bought a new position in Ironwood Pharmaceuticals during the 1st quarter valued at about $192,000. Finally, Duality Advisers LP bought a new position in Ironwood Pharmaceuticals during the 1st quarter valued at about $200,000.

Ironwood Pharmaceuticals Stock Up 0.5 %

NASDAQ IRWD opened at $10.88 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 26.52 and a current ratio of 26.52. The company has a market capitalization of $1.67 billion, a P/E ratio of 10.77 and a beta of 1.04. Ironwood Pharmaceuticals, Inc. has a one year low of $10.13 and a one year high of $14.21. The stock has a 50 day moving average price of $11.64 and a 200-day moving average price of $11.71.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.10). The company had revenue of $97.23 million during the quarter, compared to the consensus estimate of $103.51 million. Ironwood Pharmaceuticals had a return on equity of 31.01% and a net margin of 41.65%. The firm’s quarterly revenue was down 6.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.34 earnings per share. As a group, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on IRWD. Capital One Financial began coverage on shares of Ironwood Pharmaceuticals in a research note on Friday. They set an “overweight” rating and a $15.00 target price on the stock. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, June 15th. Finally, Wells Fargo & Company upped their target price on shares of Ironwood Pharmaceuticals from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 16th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

Insider Buying and Selling

In other news, COO Jason Rickard sold 18,041 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $11.75, for a total transaction of $211,981.75. Following the completion of the sale, the chief operating officer now directly owns 376,730 shares in the company, valued at $4,426,577.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, COO Jason Rickard sold 18,041 shares of the business’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $11.75, for a total transaction of $211,981.75. Following the completion of the sale, the chief operating officer now directly owns 376,730 shares of the company’s stock, valued at $4,426,577.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark G. Currie sold 70,000 shares of the business’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $11.78, for a total transaction of $824,600.00. Following the sale, the director now directly owns 521,758 shares of the company’s stock, valued at $6,146,309.24. The disclosure for this sale can be found here. Insiders sold a total of 329,222 shares of company stock worth $3,906,512 over the last three months. 13.10% of the stock is owned by insiders.

Ironwood Pharmaceuticals Profile

(Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Recommended Stories

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.